LUNAPHORE
6.2.2020 11:32:13 CET | Business Wire | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research and tissue diagnostics, announces the first closing of its Series C funding, amounting to CHF 23M. The round was led by the Japanese strategic investor PHC Holdings Corporation (hereafter, PHCHD), a global healthcare company that owns Epredia, a leading provider of comprehensive solutions for precision cancer diagnostics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200206005367/en/
The closing of the oversubscribed round was finalized on January 15, 2020. Existing investors including Redalpine Venture Partners, OCCIDENT and Alpana Ventures have also participated in this financing round.
“We are thrilled by the confidence placed in Lunaphore by our existing investors as well as the new ones in this financing round. The interest of global players in healthcare, like PHCHD demonstrates the relevance and added value of Lunaphore’s technology and confirms its high potential to transform the field of tissue analytics” said Ata Tuna Ciftlik, Lunaphore’s CEO, and added “We’re one step closer to fulfilling our vision of enabling highly sophisticated new-generation tissue analytics tests with our unique automation capabilities. The expertise and rapidly expanding network of the PHC Group and the specialist knowledge of the anatomical pathology field at Epredia will both help us gain scale and speed in this process”.
Lunaphore will invest the proceeds of Series C funding in market and product expansion. This includes a US market entry, the ramp up of activities in Europe and the development of next generation of instruments.
“We are delighted that PHCHD has invested in one of the most exciting players in tissue staining” said James Post, President of Epredia, a PHC Group portfolio company. “We believe that their technology has the potential to help revolutionize tissue analytics and greatly improve the workflow for pathologists and immuno-oncology researchers. We look forward to working together with Lunaphore to further develop their highly innovative solutions and bring them to market to help further enhance cancer research and diagnostics.” Mr. Post has joined Lunaphore’s Board of Directors as part of the transaction.
“This investment is a strong strategic fit for PHCHD, as we look to invest further in our diagnostics business,” explained Michael Kloss, President and CEO of PHCHD. “Lunaphore’s tissue staining products complement the portfolio we currently have in Epredia and we believe there is a strong opportunity for growth in their business.”
Epredia was created in June 2019 following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings Corporation. Epredia’s portfolio includes microscope slides, instruments and consumables and they are committed to providing high quality products and services to enhance precision cancer diagnostics.
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue analytics and has been recognized as one of the most innovative companies nationally and internationally. For further information on Lunaphore and its products, please visit www.lunaphore.com
.
About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company with its subsidiaries including PHC Corporation, Epredia, LSI Medience Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnostics, life sciences and healthcare services. PHC Holdings Corporation group’s consolidated net sales in FY2018 was 186.8 billion yen with global distribution of products and services in more than 125 countries. For further information on PHC Holdings Corporation, please visit www.phchd.com/global
.
About Epredia
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics. Powered by key brands, including Erie, Menzel, Microm, Shandon, and Richard Allan, Epredia’s portfolio includes microscope slides, instruments and consumables. Established following the acquisition by PHC Holdings Corporation in 2019, Epredia has major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world. For further information on Epredia and its products, please visit www.epredia.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005367/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM, a Global Leader in Quantum Computing, and Real Asset Acquisition Corp. Announce Upsized USD 146 million PIPE with New Commitment from Ilmarinen2.6.2026 16:17:00 CEST | Press release
IQM in conjunction with its SPAC partner, Real Asset Acquisition Corp., increased commitments to its PIPE due to upsized demand. This additional commitment comes from a new investor, Ilmarinen, one of Finland’s largest private earnings-related pension insurance companies. This brings total PIPE commitments from leading new and existing investors to over USD 146 million. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and a cash position expected to be up to EUR 406 million (USD 477 million1). Significant business momentum, with 2025 revenue of EUR 31 million (USD 36 million2). IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”) and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced an additional PIPE commitment from Ilmarinen in connection with the previously announced business combination between IQM and RAA
Laserfiche Launches on AWS Marketplace, Bringing Intelligent Content Management to the Enterprise2.6.2026 16:00:00 CEST | Press release
Organizations can now seamlessly procure Laserfiche document management to support and scale information governance and workflow automation. Laserfiche — the leading SaaS provider of intelligent content management — has partnered with AWS to make Laserfiche available through AWS Marketplace. This collaboration enables AWS customers to seamlessly procure Laserfiche’s document management platform to manage content, automate workflows and implement agentic AI capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602537198/en/ Laserfiche intelligent content management is now available to procure directly through AWS Marketplace. “We’re excited about this evolution of our long-standing partnership with AWS,” said Thomas Phelps, Laserfiche senior vice president of corporate strategy and CIO. “AWS Marketplace provides a near-frictionless experience for Laserfiche direct customers who want to accept negotiated private offe
Experian Brings Trusted Agentic AI to Financial Services With the Launch of Agent Operating System™2.6.2026 15:05:00 CEST | Press release
A new core capability within Experian’s Ascend Platform, designed to help financial services organisations safely scale agentic AI across the lending lifecycleBrings together Experian, client and partner AI agents within a trusted operating layer for data, decisioning, governance and control55% of consumers say they would allow an AI agent to make an autonomous purchase on their behalfServiceNow becomes first partner to integrate with Experian’s Agent Operating System Experian today announces the launch of the Agent Operating System™, a trusted agentic AI layer within the Experian Ascend Platform, unveiled at Money20/20 Europe. The Experian Agent Operating System is designed to help financial services organisations move successfully beyond AI experimentation and safely scale agentic AI to transform decision-making, customer experiences, and day-to-day operations. It enables AI agents from Experian, clients and partners to work together through a common trust, semantic and orchestration
Lenovo Technology Powers FIFA World Cup 2026™ Operations and Strengthens AI-Driven Broadcast2.6.2026 15:00:00 CEST | Press release
Lenovo’s Near Real-Time AI Infrastructure Enables IPTV Delivery, Operational Control, and Transformative Fan Experiences at Unprecedented Global Scale Lenovo today announced it is delivering a near real-time AI-powered infrastructure platform for the FIFA World Cup 2026™ to enable ultra-low-latency IPTV (Internet Protocol Television) video distribution in addition to the traditional cable and satellite broadcast, intelligent content delivery, and mission-critical decision-making across the event ecosystem and operations. As the world’s largest sporting event prepares for an unprecedented scale—spanning three host countries, featuring 48 teams, and engaging an estimated 6 billion fans—FIFA, broadcasters, and event operators will benefit from a live, always-on environment designed to perform at the highest level. As FIFA’s Official Technology Partner, Lenovo will deploy servers at the International Broadcast Center in Dallas, Texas, to help deliver the computing power, devices, and AI-dr
High Q Technologies and Creative Biostructure Announce Strategic Partnership Expanding Global Access to Quantum-Enabled EPR Spectroscopy2.6.2026 15:00:00 CEST | Press release
Collaboration Aims to Accelerate Adoption of EPR Spectroscopy in Structural Biology and Drug Discovery High Q Technologies, a developer of quantum-enabled electron paramagnetic resonance (EPR) spectroscopy systems, and Creative Biostructure, a structural biology Contract Research Organization, today announced a strategic partnership to support broader adoption of EPR spectroscopy for studying protein dynamics in pharmaceutical and biotechnology research. EPR spectroscopy is increasingly relevant as drug discovery turns toward disordered, flexible, and disease‑relevant protein systems that cannot be fully understood through static structural methods alone. However, broad adoption of EPR has historically been limited by instrument and workflow complexity, and the need for dedicated technical expertise in experimental design and data interpretation. Leveraging quantum sensor technology, FATHOM® EPR has overcome these challenges. By providing unique measurements of long‑range distances, FA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom